According to the TCGA data, the functions of less frequent somatic mutations in Nrf2 glycation sites, viz., R499W, R569C, and R569H are yet to be investigated in cancers such as colorectal cancer, endometrial cancer, and melanomas. This evidence concerns the gene NFE2L2 and cancer.